Finanzen von InMed Pharmaceuticals Inc (INM)INMInMed Pharmaceuticals Inc

InMed Pharmaceuticals Inc (INM) generates its revenue primarily from BayMedica, which accounts for 100.0% of total sales, equivalent to $1.30M. Understanding this concentration is critical for investors evaluating how INM navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, InMed Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 2.22%, provide a clear picture of how effectively INM converts its operational activities into shareholder value.

In the context of the broader market, INM competes directly with industry leaders such as PTN and MBRX. With a market capitalization of $7.92M, it holds a significant position in the sector. When comparing efficiency, INM's gross margin of N/A stands against PTN's 100.00% and MBRX's N/A. Such benchmarking helps identify whether InMed Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

The company has shown fluctuating revenue, with the latest quarter reporting 2,057,800,337 USD in revenue, but still faces significant net losses. The gross margin was notably low in recent quarters, with a gross profit of 306,938,880 USD in Q4 2026, indicating some recovery.